Clinical Trial Update: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing pertuzumab with trastuzumab and an aromatase inhibitor in metastatic HER2-positive, hormone receptor-positive advanced breast cancer has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-06-07